Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: A randomized, open-label study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 1, 2011, Pages

  Thase, Michael E ^a   Ninan, Philip T ^b   Musgnung, Jeff J ^b   Trivedi, Madhukar H ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; HYPERTENSION; INSOMNIA; INTERVIEW; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SUICIDE ATTEMPT; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 79952809764     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.10m00979blu     Document Type: Article

References (51)

1. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55(8):694-700. PubMed doi:10.1001/archpsyc.55.8.694
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475. PubMed doi:10.4088/JCP.v64n1211
3. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85-94. PubMed
4. Coyne JC, Fechner-Bates S, Schwenk TL. Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry. 1994;16(4):267-276. PubMeddoi:10.1016/0163-8343(94)90006-X
5. Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med. 1995;4(2):99-105. PubMed doi:10.1001/archfami.4.2.99
6. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry. 1993;15(6):399-408. PubMed doi:10.1016/0163-8343(93)90009-D
7. Clinical Practice Guidelines Number 5: Depression in Primary Care: Overview of Mood Disorders. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsarchive&part=A14485#A14600. Accessed October 1, 2010.
8. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 suppl):1-45. PubMed
9. Areán PA, Alvidrez J. Treating depressive disorders: who responds, who does not respond, and who do we need to study? J Fam Pract. 2001;50(6):E2. PubMed
10. Simon GE, Lin EH, Katon W, et al. Outcomes of "inadequate" antidepressant treatment. J Gen Intern Med. 1995;10(12):663-670. PubMed doi:10.1007/BF02602759
11. Simon GE, Von Korff M, Rutter CM, et al. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001;58(4):395-401. PubMeddoi:10.1001/archpsyc.58.4.395
12. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947-2955. PubMeddoi:10.1001/jama.286.23.2947
13. Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004;164(11):1197-1204. PubMeddoi:10.1001/archinte.164.11.1197
14. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180(5):396-404. PubMed doi:10.1192/bjp.180.5.396
15. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178(3):234-241. PubMeddoi:10.1192/bjp.178.3.234
16. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179(1):15-22. PubMed doi:10.1192/bjp.179.1.15
17. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082-3088. PubMeddoi:10.1001/jama.283.23.3082
18. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62(2):190-198. PubMeddoi:10.1001/archpsyc.62.2.190
19. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157(6):968-974. PubMed doi:10.1176/appi.ajp.157.6.968
20. Liebowitz MR, Asnis G, Mangano R, et al. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry. 2009;70(4):550-561. PubMed doi:10.4088/JCP.08m04238
21. Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22(9):1825-1837. PubMed doi:10.1185/030079906X132415
22. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63(4):424-434. PubMeddoi:10.1016/j.biopsych.2007.06.027
23. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry. 2008;63(7):699-704. PubMed doi:10.1016/j.biopsych.2007.08.010
24. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002;52(12):1166-1174. PubMed doi:10.1016/S0006-3223(02)01425-7
25. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009;259(3):172-185. PubMed doi:10.1007/s00406-008-0849-0
26. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard-and higher-dosing strategies. J Clin Psychopharmacol. 2006;26(3):250-258. PubMeddoi:10.1097/01.jcp.0000219922.19305.08
27. Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. 2009;14(6):326-333. PubMed
28. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161-175. PubMeddoi:10.1185/03007990802622726
29. Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl). 2008;196(4):511-520, discussion 521-522. PubMed doi:10.1007/s00213-007-0975-9
30. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006;31(2):122-131. PubMed
31. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50(1):57-64. PubMed doi:10.1159/000078225
32. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry. 1999;5:57-63.
33. McPartlin GM, Reynolds A, Anderson C, et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry. 1998;4:127-132.
34. Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Psychiatry. 1997;3:51-58.
35. Kobak KA, Taylor LH, Dottl SL, et al. A computer-administered telephone interview to identify mental disorders. JAMA. 1997;278(11):905-910. PubMeddoi:10.1001/jama.278.11.905
36. Kobak KA, Taylor LH, Dottl SL, et al. Computerized screening for psychiatric disorders in an outpatient community mental health clinic. Psychiatr Serv. 1997;48(8):1048-1057. PubMed
37. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. PubMed doi:10.1136/jnnp.23.1.56
38. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51(3):161-170. PubMed doi:10.1111/j.1600-0447.1975.tb00002.x
39. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. PubMed doi:10.1016/S0006-3223(02)01866-8
40. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370. PubMed doi:10.1111/j.1600-0447.1983.tb09716.x
41. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976:217-222.
42. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry. 1989;46(11):971-982, discussion 983. PubMed
43. Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res. 2005;39(2):145-150. PubMed doi:10.1016/j.jpsychires.2004.06.005
44. Mallick R, Chen J, Entsuah AR, et al. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry. 2003;64(3):321-330. PubMed doi:10.4088/JCP.v64n0315
45. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007;62(12):1371-1379. PubMeddoi:10.1016/j.biopsych.2007.04.040
46. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11(1-2):9-21. PubMed doi:10.1081/BIP-100104194
47. Mallinckrodt CH, Sanger TM, Dubé S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754-760. PubMeddoi:10.1016/S0006-3223(02)01867-X
48. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53. PubMeddoi:10.1001/jama.2009.1943
49. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45. PubMed doi:10.1371/journal.pmed.0050045
50. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260. PubMeddoi:10.1056/NEJMsa065779
51. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9):1167. PubMed doi:10.1176/appi.ps.60.9.1167